NATURAL KILLER CELLS: THE QUEST TOWARDS A CURE

Living Drugs in a Bag® therapy

OUR WAR AGAINST CANCER

Harnessing Nature’s Immune System

LEARN MORE

NATURAL KILLER CELLS: THE QUEST TOWARDS A CURE

Living Drugs in a Bag® therapy
OUR WAR AGAINST CANCER
Harnessing Nature’s Immune System

play video

The World’s First Off The Shelf Genetically Engineered Natural Killer Cell Platform

Meet our NK Cells

The World’s First Off The Shelf Genetically Engineered Natural Killer Cell Platform

Meet our NK Cells

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

haNK

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

taNK

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting
t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

t-haNK
previous arrow
next arrow
Slider

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

RECENT NEWS

NantKwest to Participate at Upcoming Investment Conferences

CULVER CITY, CALIFORNIA- May 15, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating in a number of investment conferences during the month of May...

NantKwest to Present at Upcoming Investment Conferences

CULVER CITY, CA - April 3, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating at a number of investment conferences during the month of April 2019....

Recent News

NantKwest to Participate at Upcoming Investment Conferences

CULVER CITY, CALIFORNIA- May 15, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating in a number of investment conferences during the month of May...

NantKwest to Present at Upcoming Investment Conferences

CULVER CITY, CA - April 3, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating at a number of investment conferences during the month of April 2019....